INVO Fertility, Inc (NASDAQ:IVF) Short Interest Up 461.7% in June

INVO Fertility, Inc (NASDAQ:IVF) was the recipient of a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 760,242 shares, an increase of 461.7% from the June 15th total of 135,347 shares. Currently, 42.8% of the shares of the company are sold short. Based on an average trading volume of 12,658,939 shares, the short-interest ratio is presently 0.1 days.

Institutional Trading of INVO Fertility

An institutional investor recently bought a new position in INVO Fertility stock. Citadel Advisors LLC purchased a new stake in INVO Fertility, Inc (NASDAQ:IVF) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned 1.19% of INVO Fertility as of its most recent filing with the SEC. 12.02% of the stock is currently owned by hedge funds and other institutional investors.

INVO Fertility Price Performance

Shares of IVF stock traded down $0.03 during mid-day trading on Friday, hitting $1.13. 106,024 shares of the stock were exchanged, compared to its average volume of 6,563,751. The firm has a fifty day moving average of $1.58 and a 200 day moving average of $3.33. The company has a quick ratio of 0.87, a current ratio of 0.90 and a debt-to-equity ratio of 0.05. INVO Fertility has a 52-week low of $1.13 and a 52-week high of $169.60. The company has a market cap of $2.02 million, a PE ratio of -0.00 and a beta of 2.28.

INVO Fertility (NASDAQ:IVF) last announced its quarterly earnings results on Monday, June 22nd. The company reported ($3.38) earnings per share for the quarter. The business had revenue of $2.02 million during the quarter. INVO Fertility had a negative net margin of 183.75% and a negative return on equity of 420.62%.

Analyst Ratings Changes

Separately, Weiss Ratings raised INVO Fertility from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, INVO Fertility has an average rating of “Moderate Buy” and an average price target of $20.00.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.